Study of the Spread of COVID-19 in Saint Petersburg, Russia

A Population-Based Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Saint Petersburg, Russia: Longitudinal Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04406038

Enrollment

1038

Registered

2020-05-28

Start date

2020-05-27

Completion date

2023-11-01

Last updated

2023-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19

Keywords

seroprevalence, covid-19, sars-cov-2

Brief summary

Seroprevalence study of COVID-19 in Saint Petersburg, Russia is a regional longitudinal cohort study aiming to evaluate the spread dynamics of the COVID-19 disease in the population of Saint Petersburg. Clinically asymptomatic adults are sampled from the population using random digit dialing and tested for the presence of SARS-CoV-2-specific antibodies in the blood serum. Data collection and serial sampling of the same individuals spans four weeks and is conducted every two weeks in order to understand both the spread of the virus in the population.

Detailed description

At least 1 000 individuals, 18 years old and older, are randomly sampled using random digit dialing from the population of Saint Petersburg, Russia. Random sampling is performed by a survey company on the list of mobile phone numbers with designated geography prefixes of St. Petersburg. The baseline questionnaire for computer-assisted telephone interview includes travel history, medical history, and socio-economic status of the respondents. Sampled individuals are then invited to the clinic for blood sampling, their refusal to participate is recorded. Collected blood samples are used for SARS-CoV-2-specific antibodies testing. Data and sample collection spans four weeks and is conducted every two weeks. Participants complete additional questionnaires in the clinic providing information on medical history, history of allergies, chronic disease, smoking, and medication taken regularly. Contact tracing data and environmental conditions of the household are reсorded.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Individuals sampled from the population of Saint Petersburg, Russia using random digit dialling. * Subjects aged 18 and older of both genders. * Asymptomatic at the time of blood draw. * Written informed consent for a blood draw, SARS-COV-2 antibody test, and data collection.

Exclusion criteria

* Presence of fever or cough or respiratory distress at the time of blood test not attributable to other known chronic disease. * Age under 18. * Any health condition that may be a contraindication towards blood sampling in out-patient clinic. * Residence in Kolpinskiy, Kurortniy, Krasnoselsky, Kronshtadtskiy, Petrodvorcoviy, Pushkinskiy districts of St. Petersburg.

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of the SARS-COV-2 infection in Saint Petersburg, Russia	Measured with two-week (14 days) intervals	Measured by SARS-CoV-2-specific antibodies serial testing and corrected for volunteer bias and test characteristics.

Secondary

Measure	Time frame	Description
Prevalence odds ratios	Measured with two-week (14 days) intervals	Comparison of prevalence by age, sex and socioeconomic strata.
Immune response dynamics	Measured with two-week (14 days) intervals	Seropositivity, seroreversion and seroconversion.

Countries

Russia

Outcome results